AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
AstraZeneca PLC News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,519.32 | 94.35 | -0.37% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,666.44 | 17.02 | -0.46% |